Can Pfizer Bank on New Immunotherapy Bavencio for Growth? – Nasdaq
|
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
Nasdaq As demand for immuno-oncology drugs and their combinations rises, Pfizer, Inc. 's PFE newly approved immunotherapy, Bavencio, is being considered a significant top-line driver for this New York-based pharma giant. Pfizer's shares are up 5.8% so far … |
